These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16752933)

  • 21. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatotoxicity of chemotherapeutic and oncologic agents.
    King PD; Perry MC
    Gastroenterol Clin North Am; 1995 Dec; 24(4):969-90. PubMed ID: 8749907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
    Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Liver function assessment in oncology practice].
    Tomášek J; Prášek J; Kiss I; Husová L; Podhorec J
    Klin Onkol; 2012; 25(6):427-33. PubMed ID: 23301644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics in patients with liver disease.
    McLean AJ; Morgan DJ
    Clin Pharmacokinet; 1991 Jul; 21(1):42-69. PubMed ID: 1914341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hepatotoxicity of chemotherapy].
    Okamoto R; Maeda Y; Sasaki T
    Nihon Rinsho; 2003 Jun; 61(6):978-83. PubMed ID: 12806946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Pharmacologic Adverse Effects in Advanced Liver Disease.
    García-Cortés M; García-García A
    Clin Drug Investig; 2022 Jun; 42(Suppl 1):33-38. PubMed ID: 35522395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs.
    Notenboom S; Weigand KM; Proost JH; van Lipzig MMH; van de Steeg E; van den Broek PHH; Greupink R; Russel FGM; Groothuis GMM
    Eur J Pharm Sci; 2018 Mar; 115():175-184. PubMed ID: 29309877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients with cancer and liver impairment.
    Palmieri C; Macpherson IR
    ESMO Open; 2021 Jun; 6(3):100162. PubMed ID: 34098229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hepatic complications of chemotherapy. From trivial cytolysis to hepatic veno-occlusive disease].
    Baron F; Beguin Y
    Rev Med Liege; 1997 Feb; 52(2):93-7. PubMed ID: 9173491
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatotoxicity of chemotherapy.
    Floyd J; Mirza I; Sachs B; Perry MC
    Semin Oncol; 2006 Feb; 33(1):50-67. PubMed ID: 16473644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
    Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
    J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Radioisotope study of the absorptive-secretory function of the liver in polychemotherapy of stomach cancer].
    Tabakman II; Raevskiĭ IG; Kalika VL; Afanas'eva EA; Basova GP
    Med Radiol (Mosk); 1971 Sep; 16(9):3-8. PubMed ID: 5146209
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
    El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Acute hepatic necrosis in a patient treated with cyproterone acetate].
    Lombardi A; Ferrazza P; Castaldi F; Covotta L; Tesoriere A; Urbano V; Midiri G
    G Chir; 1998 Apr; 19(4):161-3. PubMed ID: 9628065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center.
    Ettel M; Gonzalez GA; Gera S; Eze O; Sigal S; Park JS; Xu R
    Hum Pathol; 2017 Oct; 68():92-98. PubMed ID: 28873351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Liver damage caused by psychopharmaceuticals].
    Altomare E; Vendemiale G; Procacci V; Giovine A; Di Reda N; Albano O
    Clin Ter; 1989 Nov; 131(4):247-51. PubMed ID: 2532094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic dysfunction in patients with carcinoma who are severely thrombocytopenic and immunosuppressed.
    Lazarus HM; Creger RJ; Fox RM; Cooper BW; Jacobs G; Stellato TA
    J Am Coll Surg; 1994 Oct; 179(4):433-9. PubMed ID: 7921393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug control of steroid metabolism by the hepatic endoplasmic reticulum.
    Feuer G
    Drug Metab Rev; 1983; 14(6):1119-44. PubMed ID: 6373207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.